No evidence of added benefit for most new drugs entering German healthcare system
More than half of new drugs entering the German healthcare system have not been shown to add benefit, argue researchers in The BMJ today. Beate Wieseler and colleagues at the German health technology assessment agency IQWiG (Institute for Quality and Efficiency in Health Care) say that international drug development processes and policies are responsible and… Read More »